Hodgkin Lymphoma: ESMO Clinical Practice Guidelines

Published in 2018 – Ann Oncol (2018) 29 (Suppl 4): iv19–iv29
Authors: D. A. Eichenauer, B. M. P. Aleman, M. André, M. Federico, M. Hutchings, T. Illidge, A. Engert & M. Ladetto, on behalf of the ESMO Guidelines Committee

The 2018 ESMO Clinical Practice Guidelines on Hodgkin lymphoma (HL) are based on results from recent studies and analyses. New recommendations are given regarding treatment with BEACOPPescalated, brentuximab vedotin and anti-PD-1 antibodies. An updated recommendation for regular follow-up comprising screening examinations for malignant and non-malignant late sequelae is included, as therapy-related late effects are frequently observed in HL survivors.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings